These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

236 related articles for article (PubMed ID: 26836429)

  • 41. Insulin detemir, does a new century bring a better basal insulin?
    Hordern SV; Russell-Jones DL
    Int J Clin Pract; 2005 Jun; 59(6):730-9. PubMed ID: 15924603
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Insulin degludec products approved for diabetes.
    Traynor K
    Am J Health Syst Pharm; 2015 Nov; 72(21):1834. PubMed ID: 26490811
    [No Abstract]   [Full Text] [Related]  

  • 43. Insulin therapy-realising the potential.
    Nattrass M
    Int J Obes Relat Metab Disord; 2004 Sep; 28 Suppl 2():S1-2. PubMed ID: 15306830
    [No Abstract]   [Full Text] [Related]  

  • 44. Combined use of regular and crystalline protamine (NPH) insulins in the treatment of severe diabetes.
    Oakley W; Hill D; Oakley N
    Diabetes; 1966 Mar; 15(3):219-22. PubMed ID: 5909501
    [No Abstract]   [Full Text] [Related]  

  • 45. [Antidiabetics. 42].
    Jacker HJ
    Pharm Prax; 1969 Dec; 12():270-9. PubMed ID: 4913446
    [No Abstract]   [Full Text] [Related]  

  • 46. Insulin glargine.
    Bolli GB; Owens DR
    Lancet; 2000 Aug; 356(9228):443-5. PubMed ID: 10981882
    [No Abstract]   [Full Text] [Related]  

  • 47. [Experiences in the treatment of diabetes with insulins of monocomponent (MC) and monospecies (MS) type].
    Andreani D; Iavicoli M; Colletti A; Menzinger G
    Folia Endocrinol; 1972 Dec; 25(6):516-39. PubMed ID: 4581824
    [No Abstract]   [Full Text] [Related]  

  • 48. Insulin detemir (levemir), a new long-acting insulin.
    Med Lett Drugs Ther; 2006 Jul; 48(1238):54-5. PubMed ID: 16841022
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Newer insulins in type 2 diabetes.
    Gale EA
    BMJ; 2012 Sep; 345():e4611. PubMed ID: 22968720
    [No Abstract]   [Full Text] [Related]  

  • 50. [Biosimilar insulines - new possibilities of diabetes treatment].
    Škrha J
    Vnitr Lek; 2015 Apr; 61(4):301-3. PubMed ID: 25894258
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Clinical experience with monocomponent insulins in management of diabetes mellitus-- a preliminary report.
    Kumar V; Ahuja MM
    J Assoc Physicians India; 1980 Oct; 28(10):361-4. PubMed ID: 7014550
    [No Abstract]   [Full Text] [Related]  

  • 52. The half-life of 131 I-insulin in different groups of patients compared with normal subjects.
    van Rooyen RJ; de Bruin EJ; Bieler EU; Hoog JM
    S Afr Med J; 1972 Dec; 46(49):1927-31. PubMed ID: 4631796
    [No Abstract]   [Full Text] [Related]  

  • 53. [Immunoreactive insulin in the blood of patients with diabetes treated with insulin and diabetol].
    Smyk I
    Wiad Lek; 1980 Nov; 33(22):1803-8. PubMed ID: 7010794
    [No Abstract]   [Full Text] [Related]  

  • 54. Formulary Considerations for Insulins Approved Through the 505(b)(2) "Follow-on" Pathway.
    Rasmussen JT; Ipema HJ
    Ann Pharmacother; 2019 Feb; 53(2):204-210. PubMed ID: 30122087
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Trends in Medicaid Prices, Market Share, and Spending on Long-Acting Insulins, 2006-2018.
    Hernandez I; Good CB; Shrank WH; Gellad WF
    JAMA; 2019 Apr; 321(16):1627-1629. PubMed ID: 30907933
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Clinical therapeutics. Realising the value of modern insulins: reaching further with rapid-acting insulin analogues. XIX World Diabetes Congress, Cape Town, South Africa, December 3, 2006. Forward.
    Heise T
    Clin Ther; 2007; 29 Suppl D():S133-4. PubMed ID: 18504874
    [No Abstract]   [Full Text] [Related]  

  • 57. Miscibility of short- and intermediate-acting insulins.
    Heine RJ
    Neth J Med; 1985; 28 Suppl 1():12-4. PubMed ID: 3892332
    [No Abstract]   [Full Text] [Related]  

  • 58. The price paradox of biosimilar-like long-acting insulin.
    Mouslim MC; Rashidi ES; Levy JF; Socal MP; Trujillo AJ
    Am J Manag Care; 2022 Nov; 28(11):e405-e410. PubMed ID: 36374658
    [TBL] [Abstract][Full Text] [Related]  

  • 59. New Insulins, Biosimilars, and Insulin Therapy.
    Danne T; Heinemann L; Bolinder J
    Diabetes Technol Ther; 2022 Mar; 24(S1):S35-S57. PubMed ID: 35475698
    [No Abstract]   [Full Text] [Related]  

  • 60. Insulin degludec--the impact of a new basal insulin on care in type 2 diabetes.
    Khunti K; Cos X; Rutten G
    Prim Care Diabetes; 2014 Jul; 8(2):119-25. PubMed ID: 24207030
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.